---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-083850"
form_type: "8-K"
ticker: "CVRX"
cik: "0001235912"
company_name: "CVRx, Inc."
filed_at: "2023-07-25T23:59:59+00:00"
generated_at: "2026-06-13T02:52:09.147534+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CVRx Q2 revenue $9.5M (+89% YoY); raises FY 2023 revenue guidance

## Summary
- Q2 total revenue $9.5M, +89% YoY; US HF revenue $8.3M, +119% YoY.
- Net loss $11.7M ($0.56 per share) vs $11.1M ($0.54 per share) in Q2 2022.
- Active US implanting centers grew to 140, up 97% from June 2022.
- FY 2023 revenue guidance raised to $37.0-38.5M (from $35.5-38.0M).
- PMA supplement filed with FDA for Barostim indication expansion in June 2023.

## SEC filing metadata
- accession: 0001104659-23-083850
- form_type: 8-K
- ticker: CVRX
- cik: 0001235912
- company_name: CVRx, Inc.
- filed_at: 2023-07-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1235912/000110465923083850/0001104659-23-083850-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1235912/000110465923083850/tm2321888d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-083850
- JSON: https://secwatch.observer/filing/0001104659-23-083850.json
- Plain text: https://secwatch.observer/filing/0001104659-23-083850.txt

## Key facts
- Earnings Releases
  CVRx, Inc. reported the quarter ended June 30, 2023 results: revenue $9.5 million, net income $11.7 million, EPS $0.56 per share. Guidance raised.
  - Period: the quarter ended June 30, 2023
  - Revenue: $9.5 million
  - Net income: $11.7 million
  - EPS: $0.56 per share
  - Guidance: raised
  - Result: reported results
  source text: diseases, today announced its financial and operating results for the second quarter of 2023. Recent Highlights · Total revenue for the second quarter of 2023 was $ 9.5 million, an increase of 89 % over prior year quarter · U.S. Heart Failure (HF) revenue for the second quarter of 2023 was $ 8.3 million compared to $ 3.8 in the prior year quarter, an
  evidence_url: https://www.sec.gov/Archives/edgar/data/1235912/000110465923083850/0001104659-23-083850-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.